Immune checkpoint inhibitors (ICIs) have advanced rapidly in oncology; potential biomarkers for urachal carcinoma include mismatch repair (MMR) deficiency and tumor cell PD-L1 positivity. This evidence concerns the gene CD274 and neoplasm.